News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elixir Pharmaceuticals Plans $86.25 Million IPO


9/24/2007 6:32:32 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. Credit Suisse Securities (USA) LLC will act as sole book-runner for the offering. Pacific Growth Equities, LLC and Leerink Swann LLC will act as co-managers.

The number of shares to be offered and the price range for the offering have not yet been determined. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained from Credit Suisse Securities (USA) LLC, Prospectus Department, Eleven Madison Avenue, Level 1B, New York, NY 10010, (212) 325-2580.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Elixir Pharmaceuticals, Inc.

Elixir Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity.

Contact: Elixir Pharmaceuticals William Heiden, 617-995-7000 or Media: Burns McClellan for Elixir Pharmaceuticals: 212-213-0006 Justin Jackson jjackson@burnsmc.com or Jason Farber jfarber@burnsmc.com or Investors: Juliane Snowden jsnowden@burnsmc.com or Nicki Kahner nkahner@burnsmc.com

Source: Elixir Pharmaceuticals, Inc.


Read at BioSpace.com
Read at Reuters

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES